Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials

Matsuda,Ayako; Yamaoka,Kazue; Tango,Toshiro

doi:10.3892/etm.2011.368

Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trials

Authors:
- Ayako Matsuda
- Kazue Yamaoka
- Toshiro Tango
View Affiliations

Affiliations: Surveillance Division Population-Based Cancer Registry Section, Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan, Teikyo University, Graduate School of Public Health, Tokyo, Japan, Center for Medical Statistics, Tokyo, Japan
Published online on: October 18, 2011 https://doi.org/10.3892/etm.2011.368
Pages: 134-140

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For advanced non-small cell lung cancer (NSCLC) patients, the only treatment option is palliative therapy, with the aim of prolonging overall survival and improving disease‑related symptoms and quality of life (QOL). However, to date, the effect of palliative care on QOL has not yet been thoroughly examined, and there has been no meta-analysis of previous studies reporting QOL outcomes following palliative care. We consider that it is important to evaluate not only survival and/or response rates, but also QOL in patients with advanced NSCLC receiving palliative chemotherapy. The aim of the present study was to obtain useful information for the selection of suitable chemotherapy regimens for advanced NSCLC patients, taking into consideration QOL, and to demonstrate the importance of QOL assessments during treatment. We performed a meta-analysis of QOL outcomes following treatments that compared carboplatin- to cisplatin-based chemotherapy. Trials were eligible for analysis if they had compared carboplatin- to cisplatin-based chemotherapy in advanced NSCLC patients who had not received prior chemotherapy, and if these studies reported QOL data. In the six trials eligible for analysis, 2,405 patients were randomized to receive cisplatin-based or carboplatin-based chemotherapy. The patients who received carboplatin-based chemotherapy had higher global QOL and less severe symptoms than those who received cisplatin-based chemotherapy. The survival rate, which was the primary outcome in clinical trials, and the response rate did not differ significantly between the two treatment groups. It is important to evaluate QOL in addition to the survival and response rates for advanced NSCLC, particularly when the treatment is palliative.

View Figures

View References

1.	DM ParkinGlobal cancer statistics in the year 2000Lancet Oncol2533543200111905707
2.	S NovelloT Le ChevalierChemotherapy for non-small-cell lung cancer. Part 1. Early-stage diseaseOncology17357364200312661267
3.	L De PetrisL CrinòGV ScagliottiTreatment of advanced non-small cell lung cancerAnn Oncol17ii36ii412006
4.	C GridelliF PerroneF NelliQuality of life in lung cancer patientsAnn Oncol12S21S25200110.1093/annonc/12.suppl_3.S2111804379
5.	American Society of Clinical OncologyClinical practice guidelines for the treatment of unresectable non-small-cell lung cancerJ Clin Oncol152996301819979256144
6.	C PerssonU OstlundA Wennman-LarsenY WengströmP GustavssonHealth-related quality of life in significant others of patients dying from lung cancerPalliat Med22239247200810.1177/026921630708533918477718
7.	G AlbersMA EchteldHC de VetEvaluation of quality of life measures for use in palliative care: systematic reviewPalliat Med241734201010.1177/026921630934659319843620
8.	J BeitzC GneccoR JusticeQuality of life end points in cancer clinical trials: the U.S. Food and Drug Administration perspectiveJ Natl Cancer Inst Monogr20791996
9.	P HarperT PlunketD KhayatQuality trials and quality of life in non-small cell lung cancerJ Clin Oncol2130073008200310.1200/JCO.2003.05.07912837809
10.	K HottaK MatsuoH UeokaMeta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancerJ Clin Oncol2238523859200410.1200/JCO.2004.02.10915326195
11.	A ArdizzoniL BoniM TiseoCisplatin- versus carboplatin-based chemotherapy in frst-line treatment of advanced non-small cell lung cancer: an individual patient data meta-analysisJ Natl Cancer Inst99847857200710.1093/jnci/djk19617551145
12.	J JiangX LiangX ZhouA meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancerLung Cancer57348358200710.1016/j.lungcan.2007.03.01417485133
13.	NK AaronsonS AhmedzaiB BergmanThe European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst85364376199310.1093/jnci/85.5.3658433390
14.	DF CellaAE BonomiSR LloydReliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrumentLung Cancer12199220199510.1016/0169-5002(95)00450-F7655830
15.	K JamesE EisenhauerM ChristianMeasuring response in solid tumors: unidimensional versus bidimensional measurementJ Natl Cancer Inst17523528199910.1093/jnci/91.6.52310088622
16.	T TangoAn introduction to meta-analysisMedical Statistical Science Series 4Asakura bookstoreTokyo991012009
17.	A WhiteheadMeta-analysis of Controlled Clinical TrialsJohn Wiley & Sons, LtdChichester2372402002
18.	NW ScottPM FayersNK AaronsonEORTC QLQ-C30 Reference ValuesJuly2008[updated August 6, 2011]. http://groups.eortc.be/qol/downloads/reference_values_manual2008.pdf.
19.	DB PetittiMeta-analysis, Decision Analysis, and Cost-effectiveness AnalysisOxford University PressOxford, New York1161172010
20.	P SpectorAn Introduction to S and S-PlusDuxbury PressBelmont, CA1994
21.	R RosellU GatzemeierDC BetticherPhase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trialAnn Oncol1315391549200210.1093/annonc/mdf332
22.	GV ScagliottiF De MarinisM RinaldiPhase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancerJ Clin Oncol2042854291200210.1200/JCO.2002.02.06812409326
23.	S DansonMR MiddletonKJ O'ByrnePhase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinomaCancer98542553200310.1002/cncr.1153512879472
24.	A PaccagnellaA FavarettoF OnigaCisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trialLung Cancer438391200410.1016/S0169-5002(03)00280-014698542
25.	RM RuddNH GowerSG SpiroGemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer GroupJ Clin Oncol23142153200510.1200/JCO.2005.03.03715625369
26.	R BootonP LoriganH AndersonA phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)Ann Oncol17111111192006
27.	K HottaK MatsuoLong-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancerJ Thorac Oncol296200710.1097/JTO.0b013e31802bb01017410021
28.	J GoffinC LacchettiPM EllisFirst-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic reviewJ Thorac Oncol5260274201010.1097/JTO.0b013e3181c6f03520101151
29.	S MoritaK KobayashiK EguchiInfluence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear modelJpn J Clin Oncol33470476200310.1093/jjco/hyg08314594941
30.	G BuccheriF VolaD FerrignoAspects of quality-of-life in patients with lung-cancer - a 3 observer evaluation studyInt J Oncol2537544199321573589
31.	B HolznerRK BodeEA HahnEquating EORTC QLQ-C30 and FACT-G scores and its use in oncological researchEur J Cancer4231693177200610.1016/j.ejca.2006.08.01617045472
32.	MH CullenLJ BillinghamCM WoodroffeMitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of lifeJ Clin Oncol1731883194199910506617
33.	P BonomiK KimD FaircloughComparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trialJ Clin Oncol186236312000
34.	PJ HollenRJ GrallaComparison of instruments for measuring quality of life in patients with lung cancerSemin Oncol23314019968610235
35.	EditorialQuality of life and clinical trialsLancet34612199510.1016/S0140-6736(95)92643-7
36.	N ThatcherP HopwoodH AndersonImproving quality of life in patients with non-small cell lung cancer: research experience with gemcitabineEur J Cancer33813199710.1016/S0959-8049(96)00336-X9166093